Tracer library / [11C]ibrutinib
[11C]ibrutinib
Also written as [11C]Ibrutinib; [C-11]Ibrutinib
- Radionuclide
- C-11 t½ 20.36 min
- Modality
- PET
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 4
What it is
- Compound class
- Bruton's tyrosine kinase (BTK) inhibitor (small molecule, ibrutinib analog)
- Target / mechanism
- Bruton's tyrosine kinase (BTK) PMID 27043721
- Clinical application
- Autoimmune diseases; imaging in experimental autoimmune encephalomyelitis (EAE) mouse model of multiple sclerosis PMID 39355638
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| TRACERlab FX (model not stated) GE HealthCare | — | HPLC | — | — | — | 37513867 2023 Pharmaceuticals (Basel) Recently, Scott, Shao, and co-workers developed an automated and good manufacturing practice (GMP)-compliant "in-loop" 11C-carbonylation procedure using a modified GE TracerLabTM synthesis platform - three clinically relevant BTK inhibitors, [11C]ibrutinib, [11C]tolebrutinib, and [11C]evobrutinib, were synthesized at good RCYs |
| TRACERlab FX C Pro GE HealthCare | custom manifold | HPLC+SPE | 5% not corrected | >99% | precursor 11 Bristol-Myers Squibb | 27043721 2016 Bioconjug Chem the procedure was fully automated on a GE TRACERLab FXC-Pro synthesis module - gave 150 mCi of isolated and formulated product (5% non-decay corrected RCY based upon [11C]CO2; RCP >99%; specific activity = 55 mCi/μmol; pH = 6.0) |
| TracerMaker Scansys Laboratorieteknik | — | HPLC+SPE | 5.4 ± 2.5% not corrected | >99% | 3-(4-phenoxyphenyl)-1-(piperidin-3-yl)-2,3-d…3-(4-phenoxyphenyl)-1-(piperidin-3-yl)-2,3-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-amine Bristol Myer-Squibb Pharmaceuticals, Princeton, NJ, USA | 39355638 2021 Front Nucl Med The radiosynthesis of [11C]ibrutinib was fully automated using a commercial TracerMaker™ 11C synthesis platform. - [11C]Ibrutinib was synthesized in 5.4 ± 2.5% (n = 9) RCY (non-decay corrected) relative to [11C]CO2 |
| TracerMaker Scansys Laboratorieteknik | — | HPLC | 5 not corrected | — | — | 39831838 2025 ChemistryOpen was delivered to a TracerMaker synthesis platform (Scansys Laboratorieteknik, Denmark) - The fully automated syntheses yielded [11C]Ibrutinib in RCY of 5 % |
Precursor
- Common precursor
- —
- Suppliers seen in the literature
- —
- Cited suppliers in indexed syntheses
- Bristol Myer-Squibb Pharmaceuticals, Bristol-Myers Squibb
- Typical final purification
- —
Need this precursor?We can point you to suppliers for [11C]ibrutinib, or handle the enquiry for you.
Get in touchQuality control Preliminary - inferred from compound class
- Ph. Eur. monograph
- not verified No Ph. Eur. check is recorded for this entry.
- USP monograph
- not verified No USP check is recorded for this entry.
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [11C]ibrutinib.
Get in touchNotes
Added from reverse module search (stage 6); 2 article(s) with C-11. Stage set/updated at stage 39 from PMID 39355638: 'Preliminary PET/magnetic resonance imaging with [11C]ibrutinib in experimental autoimmune encephalomyelitis (EAE) mice showed a 49% higher radioactivity accumulation in the spinal cord of mice with EAE scores of 2.5 vs. sham mice.'.